8 results about "Intellectual disability" patented technology

A system is provided.SOLUTION: A system comprising: means for recording interactions between a parent and a child of a Mental Disability; means for pre-processing the recorded interactions to train a generative AI; means for the generative AI to communicate with the child after the parent dies; means for the generative AI to monitor the child for anomalous behavior; and means for providing an emergency notification if an anomaly is detected.SELECTED DRAWING: Figure 1

An object of the system according to the embodiment is to enable parents of children with developmental disabilities or intellectual disabilities to obtain appropriate information and support.SOLUTION: A system according to an embodiment includes an online platform, a AI chat bot, an analyzer, and a matcher. The online platform is for parents of children with developmental and intellectual disabilities to share information, experience, and receive assistance. The AI chat bot provides appropriate information and advice in response to a question from a parent. The analysis unit analyzes the degree and characteristics of the disorder of the child. The matching unit matches parents having children with similar symptoms on the basis of the result analyzed by the analysis unit.SELECTED DRAWING: Figure 1

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in a cell or subject, and in certain instances reducing the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, a Developmental and Epileptic Encephalopathy, an intellectual disability, or an autism spectrum disorder. Such symptoms and hallmarks include, but are not limited to seizures, hypotonia, sensory integration disorders, motor development delays and dysfunctions, intellectual and cognitive dysfunctions, movement and balance dysfunctions, visual dysfunctions, delayed language and speech, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

This article provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in cells or subjects, and in some cases, reducing the amount of SCN2A protein in cells or subjects. Such compounds, methods, and pharmaceutical compositions can be used to improve at least one symptom or marker of a disease or disorder associated with voltage-gated sodium channel proteins, such as, for example, developmental and epileptic encephalopathy, intellectual disability, or autism spectrum disorder. Such symptoms and markers include, but are not limited to, seizures, hypotonia, sensory integration dysfunction, delayed and impaired motor development, intellectual and cognitive impairment, motor and balance impairment, visual impairment, language and speech delay, gastrointestinal disorders, delayed neurodevelopment, sleep problems, and sudden unexpected death in epilepsy.

Provided herein are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA, and in certain cases, the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions can be used to improve at least one symptom or indicia of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, developmental and epileptic encephalopathies, intellectual disability, or an autism spectrum disorder. Such symptoms and indicia include, but are not limited to, seizures, hypotonia, sensory integration disorder, motor development delays and dysfunction, intellectual and cognitive dysfunction, motor and balance dysfunction, visual dysfunction, language and speech delays, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and / or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.

SYNGAP1 -related intellectual disability is a genetic neurodevelopmental disorder caused by an insufficient level of SynGAPl. Provided herein are autologous hematopoietic stem and progenitor cells transduced with a lentiviral vector expressing a modified form of SYNGAP1, and methods of making the same, which can be useful in treating patients diagnosed with SYNGAP1 -related intellectual disability.